STREPTOCOCCUS.

Yves Laure Pimentel · 70問 · 2年前

通報

問題一覧

DUE TO SUPER ANTIGENS

TSS

S.pyogenes Laboratory ID: Lancefield Serology: _____________

GRP. A SEROLOGY

Bacitracin (Taxo A) _____________ and _____________

SUCEPTIBLE AND PYR +

S.pyogenes Lancefield Serology: ____________

GROUP A SEROLOGY

S.pyogenes Treatment:

Penicillin

S.pyogenes Skin test for Scarlet fever______

DICKS TEST

S.pyogenes CHARACTERISTICS HEMOLYSIS: ALPHA BETA GAMMA

BETA HEMOLYSIS

S.pyogenes CHARACTERISTICS COMPOSED OF HYALURONIC ACID; ANTIPHAGOCYTIC

CAPSULATED

S.pyogenes CHARACTERISTICS MORE SPECIFIC TEST PYR +/-

PYR +

BACITRACIN SENSITIVE (TAXO A) FOR WHAT GROUP?

GROUP A & B

S.pyogenes CHARACTERISTICS SXT (TRIMETROPRIM S.) RESISTANT/SUSCEPTIBLE

RESISTANT

A STREPTOLYSIN WHICH IS MORE ANTIGENIC ; PRODUCE BACTE IN LARGE AMT IN INCREASE CO2

STREP. O (OXYGEN LABILE)

A STREPTOLYSIN WHICH IS DESTRUCTION OF RBCS

STREP. S (STABLE LABILE)

Lancefield Group B

S.agalactiae

S.agalactiae Lancefield Group ?

Lancefield Group B

NF of genitourinary tract - the only specie expressing B Antigen

S.agalactiae

S.agalactiae Virulence: ? – most important and only virulence factor, Sialic acid appears to be the most important component

Capsule

S.agalactiae Virulence: Capsule – most important and only virulence factor, ? appears to be the most important component of capsule

Sialic acid

ZETA POTENTIAL WHICH REPELLS WBC

Sialic acid

WHAT STREP. Neonatal Sepsis (pneumonia or meningitis) – after birth

S.agalactiae

PRINCIPAL cause of bacterial meningitis and septicemia in neonates

S.agalactiae

LEADING of death in infants in US

S.agalactiae

Tricuspid valve endocarditis in women with obstetric procedure

S.agalactiae

S.agalactiae SELECTIVE BROTH

Todd Hewitt Broth

Todd-Hewitt broth w/CNA is also known as

Lim Broth

S.agalactiae ARROWHEAD SHAPE

CAMP +

S.agalactiae Hippurate hydrolysi (+) – Hippurate + Org  Glycine + Ninhydrin indicator =

DEEP BLUE

S.agalactiae Most useful ID:

CAMP & H.H

S.agalactiae PYR +/-

PYR +

S.agalactiae SXT RESISTANCE/SUSCEPTIBLE

SXT RESISTANCE

S.agalactiae Tx

PENICILLIN

Hippurate hydrolysi (+) – Hippurate + Org -> ?+? indicator =BLUE

Glycine + Ninhydrin

S.agalactiae BACITRACIN ?

RESISTANT TAXO A

S.agalactiae HIPPURATE HYDROLYSIS POSITIVE COLOR

DEEP PURPLE COLOR

S.agalactiae HIPPURATE HYDROLYSIS NEGATIVE COLOR

NO PURPLE COLOR

DEAMINATE BY NINHYDRIN REDUCED AND BECOMES PURPLE

GLYCINE

block shape hemolysis

L. MONOCYTOGENS

OTHER THAN S. AGALACTIAE IT IS ALSO CAMP + & HH +

L. MONOCYTOGENS

WHAT GROUP IS alpha hemolytic

Group D

ARE GROUP D STREPTOCOCCI: ENTEROCOCCI

ENTEROCOCCUS FAECALIS ENTEROCOCCUS FAECIUM

ARE GROUP D STREPTOCOCCI: NON- ENTEROCOCCI

STREPTOCOCCUS BOVIS STREPTOCOCCUS EQUINUS

Group D ARE Bile esculin +/-

Bile esculin +

Group D Procedure: (+) ( ) – Esculin + Org  esculetin + Fe3+ =

Black precipitate

Group D + Controls:

E. FAECALIS

Group D - Controls:

E. COLI & S. PYOGENES

S.bovis - isolation from blood may be the first indication of ___________

GI TUMOR

- isolation from blood may be the first indication of GI TUMOR

S.bovis

GRP D STREPTOCOCCI: ENTEROCOCCI GROWTH @

10C -45 C

GRP D STREPTOCOCCI: ENTEROCOCCI INTRINSICALLY RESISTANCE TO ?

AMINOGLYCOSIDE

IMPORTANT TO SCREEN FOR HIGH LEVEL AMINOGLYCOSIDE

GRP D STREPTOCOCCI:ENTEROCOCCI

GRP D STREPTOCOCCI: ENTEROCOCCI BILE- ESCULIN ?

BILE- ESCULIN POSITIVE

SHOW RESISTANCE TO THE GLYCOPEPTIDE ANTIBIOTICS, VANCOMYCIN & RESCOPLANIN HOSPITAL ACQUIRED INFECTIONS MUTANS OF ENTEROCCOCUS THAT ARE RESISTANT TO VANCOMYCIN

VANCOMYCIN RESISTANT ENTEROCOCCI (VRE)

a common normal flora of Upper resp.tract (OROPHARYNX)

Viridans Strep

Not part of the Lancefield

Viridans Strep

Viridans Strep ALPHA hemolytic BETA hemolytic GAMMA hemolytic

ALPHA hemolytic

Viridans Strep OPTOCHIN RESISTANT / SUCEPTIBLE

Viridans Strep OPTOCHIN RESISTANT

Subacute bacterial endocarditis

Viridans Strep

Viridans Strep ARE: (5)

S.salivarius S.sanguis S.mitis S. milleri S.mutans

DENTAL PLAQUE VIRIDANS

S.mutans

Viridans Strep S.salivarius S.sanguis S.mitis S. milleri S.mutans GRAM +/-

GRAM +

ARE IN CHAINS, SMALL PINPOINT TRANSLUSCENT COLONIES

Viridans Strep S.salivarius S.sanguis S.mitis S. milleri S.mutans

Nutritionally deficient

Nutritionally Variant Streptococci (NVS)

Nutritionally Variant Streptococci (NVS) AGENTS (2)

ABIOTROPHIA GRANULICATELLA

STAPHYLOCOCCAL CROSS STREAKS; IT IS WHERE NUTRITION COME FROM

SATELLITES STAPHYLOCOCCUS

Nutritionally Variant Streptococci (NVS) Gram ____________

VARIABLE +/-

Nutritionally Variant Streptococci (NVS) REQUIREMENT FOR THEIR GROWTH PYRIDOXAL DEPENDENT/ VIT. B6

L-CYSTEINE

Nutritionally Variant Streptococci (NVS) L-CYSTEINE

PYRIDOXAL DEPENDENT/ VIT. B6

PLEOMORPHIC CELL MORPHOLOGY

Nutritionally Variant Streptococci (NVS)

Nutritionally Variant Streptococci (NVS) HEMOLYTIC PATTERN

ALPHA/ NON-HEMOLYTIC

ASSOCIATED WITH Ptx w/endocarditis and otitis

Nutritionally Variant Streptococci (NVS)

Enterococcus

Enterococcus HEMOLYTIC PATTERN

nonhemolytic or alpha hemolytic

Found in the intestinal tract

Enterococcus

CAUSES UTI

Enterococcus

HAS PSEUDOCATALASE REACTION (+)

Enterococcus

most common isolate

E.faecalis

SALT TOLERANCE TEST USING 6.5% SALT BROTH

E.faecalis

Colonize heart valves and Renal Epithelial cells

E.faecalis

E.faecalis Toxin producers:

Cytolysin and bacteriocins

E.faecium most common ____

VANCOMYCIN RESISTANT ENTEROCOCCI

most common VANCOMYCIN RESISTANT ENTEROCOCCI

E.faecium

E.faecium assoc.to _

RBC ACQUIRED KELL ANTIGEN

assoc.to RBC ACQUIRED KELL ANTIGEN

E.faecium

Other Enterococcus

E.avium E.durans

GROUP D Bile esculin

GROUP D 6.5% NaCl

GROUP D PYR

GROUP D 45oC and Alkaline pH

ENTEROCOCCUS Bile esculin

ENTEROCOCCUS 6.5% NaCl

ENTEROCOCCUS PYR

ENTEROCOCCUS SXT

RESISTANT

ENTEROCOCCUS 45oC and Alkaline pH

Phadebact D - S. equis and Viridans (PYR neg)

Negative

ENTEROCOCCUS Negative -

S. equis and Viridans (PYR neg)

ENTEROCOCCUS - S. faecalis, S. faecium, S. avium, and S. durans (PYR) positive; and S. bovis (PYR Neg)

Positive

S. durans (PYR)

positive

S. bovis (PYR ?)

Neg

other names parasitology

other names parasitology

70問 • 2年前

Yves Laure Pimentel · 111問 · 2年前

PARASITOLOGY

PARASITOLOGY

111問 • 2年前

Yves Laure Pimentel · 64問 · 2年前

HTMLBE

HTMLBE

64問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

61問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

HISTOPATHOLOGY

HISTOPATHOLOGY

69問 • 2年前

CC-2 SPECTROPHOTOMETRY

CC-2 SPECTROPHOTOMETRY

Yves Laure Pimentel · 41問 · 2年前

CC-3 ELECTROPHORESIS

CC-3 ELECTROPHORESIS

41問 • 2年前

Yves Laure Pimentel · 87問 · 2年前

AUBF LAB SAFETY

AUBF LAB SAFETY

87問 • 2年前

CSF 1

CSF 1

Yves Laure Pimentel · 82問 · 2年前

CSF 2

CSF 2

82問 • 2年前

SEMEN 1

SEMEN 1

Yves Laure Pimentel · 7問 · 2年前

SEMEN 2

SEMEN 2

7問 • 2年前

SYNOVIAL FLUID 1

SYNOVIAL FLUID 1

Yves Laure Pimentel · 6問 · 2年前

SYNOVIAL FLUID 2

SYNOVIAL FLUID 2

6問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

SEROUS FLUID

SEROUS FLUID

25問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

PLEURAL FLUID

PLEURAL FLUID

44問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

PERICARDIAL FLUID

PERICARDIAL FLUID

18問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

PERITONEAL FLUID/ ASCITIC FLUID

PERITONEAL FLUID/ ASCITIC FLUID

30問 • 2年前

Yves Laure Pimentel · 92問 · 2年前

AMNIOTIC FLUID

AMNIOTIC FLUID

92問 • 2年前

Yves Laure Pimentel · 80問 · 2年前

FECALYSIS

FECALYSIS

80問 • 2年前

Yves Laure Pimentel · 89問 · 2年前

OTHER BODY FLUIDS

OTHER BODY FLUIDS

89問 • 2年前

Yves Laure Pimentel · 86問 · 2年前

MTLBE- SUHO NOTES

MTLBE- SUHO NOTES

86問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

MTLBE..

MTLBE..

35問 • 2年前

Yves Laure Pimentel · 19問 · 1年前

CC- CHROMATOGRAPHY

CC- CHROMATOGRAPHY

19問 • 1年前

Yves Laure Pimentel · 14問 · 1年前

CC-OSMOMETRY

CC-OSMOMETRY

14問 • 1年前

Yves Laure Pimentel · 43問 · 1年前

CC-ELECTROCHEMISTRY TECHNIQUES

CC-ELECTROCHEMISTRY TECHNIQUES

43問 • 1年前

Yves Laure Pimentel · 49問 · 2年前

CC- CARBOHYDRATES

CC- CARBOHYDRATES

49問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

CC- DIABETES MELLITUS

CC- DIABETES MELLITUS

97問 • 2年前

Yves Laure Pimentel · 57問 · 2年前

MAJOR LIPOPROTEINS

MAJOR LIPOPROTEINS

57問 • 2年前

Yves Laure Pimentel · 63問 · 2年前

MINOR LIPOPROTEINS

MINOR LIPOPROTEINS

63問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PROTEINS

PROTEINS

37問 • 2年前

Yves Laure Pimentel · 91問 · 2年前

PLASMA PROTEINS 1

PLASMA PROTEINS 1

91問 • 2年前

Yves Laure Pimentel · 98問 · 2年前

PLASMA PROTEINS 2 (ALPHA 2 REGION)

PLASMA PROTEINS 2 (ALPHA 2 REGION)

98問 • 2年前

Yves Laure Pimentel · 61問 · 2年前

MISCELLANEOUS PROTEINS

MISCELLANEOUS PROTEINS

61問 • 2年前

Liver Function Test 1

Liver Function Test 1

Yves Laure Pimentel · 96問 · 2年前

Liver Function Test 2

Liver Function Test 2

96問 • 2年前

Yves Laure Pimentel · 33問 · 2年前

TUMOR MARKERS

TUMOR MARKERS

33問 • 2年前

Yves Laure Pimentel · 41問 · 2年前

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

41問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

GLYCOGEN STORAGE DISEASES

GLYCOGEN STORAGE DISEASES

17問 • 2年前

Yves Laure Pimentel · 14問 · 2年前

LIPID STORAGE DISEASES

LIPID STORAGE DISEASES

14問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

PROTEINS

PROTEINS

71問 • 2年前

Yves Laure Pimentel · 7問 · 2年前

QUICK FIRE- ELECTRODES

QUICK FIRE- ELECTRODES

7問 • 2年前

Yves Laure Pimentel · 10問 · 2年前

ELECTROLYTES

ELECTROLYTES

10問 • 2年前

Yves Laure Pimentel · 27問 · 2年前

DRUGS

DRUGS

27問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

TOXIC AGENTS:

TOXIC AGENTS:

12問 • 2年前

HEMATOLOGY 1 (HEMATOPOIESIS 1)

HEMATOLOGY 1 (HEMATOPOIESIS 1)

Yves Laure Pimentel · 29問 · 2年前

HEMATOLOGY (HEMATOPOIESIS 2)

HEMATOLOGY (HEMATOPOIESIS 2)

29問 • 2年前

Yves Laure Pimentel · 25問 · 2年前

hema diseases

hema diseases

25問 • 2年前

Yves Laure Pimentel · 43問 · 2年前

AML

AML

43問 • 2年前

Yves Laure Pimentel · 71問 · 2年前

GLOBIN SYNTHESIS

GLOBIN SYNTHESIS

71問 • 2年前

Yves Laure Pimentel · 31問 · 2年前

HEMATOLOGY REFERENCE RANGES

HEMATOLOGY REFERENCE RANGES

31問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

DISORDERS OF PRIMARY HEMOSTASIS

DISORDERS OF PRIMARY HEMOSTASIS

34問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

PLATELET DISORDERS

PLATELET DISORDERS

37問 • 2年前

CHARACTERISTICS OF CLOTTING FACTORS

CHARACTERISTICS OF CLOTTING FACTORS

Yves Laure Pimentel · 12問 · 2年前

4. CLASSIFICATION OF MACROPHAGE

4. CLASSIFICATION OF MACROPHAGE

12問 • 2年前

Yves Laure Pimentel · 39問 · 2年前

3. NATURAL OR INNATE IMMUNITY

3. NATURAL OR INNATE IMMUNITY

39問 • 2年前

Yves Laure Pimentel · 55問 · 2年前

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

55問 • 2年前

Yves Laure Pimentel · 37問 · 2年前

6. PHAGOCYTOSIS Chemotaxis

6. PHAGOCYTOSIS Chemotaxis

37問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

8. NATURE OF ANTIGEN

8. NATURE OF ANTIGEN

44問 • 2年前

Yves Laure Pimentel · 50問 · 2年前

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

50問 • 2年前

Yves Laure Pimentel · 69問 · 2年前

1. HISTORY

1. HISTORY

69問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. TYPES OF IMMUNITY

2. TYPES OF IMMUNITY

38問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

7. PHAGOCYTOSIS Engulfment and Digestion

7. PHAGOCYTOSIS Engulfment and Digestion

21問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

8. PHAGOCYTOSIS EXOCYTOSIS

8. PHAGOCYTOSIS EXOCYTOSIS

15問 • 2年前

Yves Laure Pimentel · 32問 · 2年前

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

32問 • 2年前

Yves Laure Pimentel · 30問 · 2年前

11. TRANSPLANTATION IMMUNOLOGY

11. TRANSPLANTATION IMMUNOLOGY

30問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. LYMPHOID ORGANS

2. LYMPHOID ORGANS

38問 • 2年前

Yves Laure Pimentel · 48問 · 2年前

3. CLUSTER OF DIFFERENTIATION

3. CLUSTER OF DIFFERENTIATION

48問 • 2年前

Yves Laure Pimentel · 35問 · 2年前

4. T-CELL DIFFERENTIATION

4. T-CELL DIFFERENTIATION

35問 • 2年前

Yves Laure Pimentel · 18問 · 2年前

5. T CELL IMMUNODEFICIENCIES

5. T CELL IMMUNODEFICIENCIES

18問 • 2年前

Yves Laure Pimentel · 44問 · 2年前

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

44問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

7. B CELL IMMUNODEFICIENCIES

7. B CELL IMMUNODEFICIENCIES

23問 • 2年前

Yves Laure Pimentel · 34問 · 2年前

8. COMBINED T CELL AND B CELL DEFICIENCIES

8. COMBINED T CELL AND B CELL DEFICIENCIES

34問 • 2年前

Yves Laure Pimentel · 12問 · 2年前

9. COMPARISON OF T AND B CELLS

9. COMPARISON OF T AND B CELLS

12問 • 2年前

Yves Laure Pimentel · 16問 · 2年前

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

16問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

15問 • 2年前

Yves Laure Pimentel · 79問 · 2年前

12. ANTIBODY

12. ANTIBODY

79問 • 2年前

Yves Laure Pimentel · 97問 · 2年前

13. TYPES OF ANTIBODIES

13. TYPES OF ANTIBODIES

97問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

14. MONOCLONAL ANTIBODIES

14. MONOCLONAL ANTIBODIES

11問 • 2年前

Yves Laure Pimentel · 23問 · 2年前

1. INTERLEUKINS

1. INTERLEUKINS

23問 • 2年前

Yves Laure Pimentel · 28問 · 2年前

2. INTERFERONS

2. INTERFERONS

28問 • 2年前

Yves Laure Pimentel · 8問 · 2年前

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

8問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

4. COMPLEMENT SYSTEM

4. COMPLEMENT SYSTEM

19問 • 2年前

Yves Laure Pimentel · 76問 · 2年前

15. COMPLEMENT SYSTEM

15. COMPLEMENT SYSTEM

76問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

16. SYSTEM CONTROLS/COMPLEMENT REGULATION

21問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

17. COMPLEMENT AND DISEASE STATES

17. COMPLEMENT AND DISEASE STATES

29問 • 2年前

Yves Laure Pimentel · 19問 · 2年前

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

19問 • 2年前

Yves Laure Pimentel · 22問 · 2年前

19. CYTOKINES

19. CYTOKINES

22問 • 2年前

Yves Laure Pimentel · 24問 · 2年前

20. INTERLEUKINS

20. INTERLEUKINS

24問 • 2年前

Yves Laure Pimentel · 21問 · 2年前

21. INTERFERONS, TNF, TGF, CHEMOKINE

21. INTERFERONS, TNF, TGF, CHEMOKINE

21問 • 2年前

Yves Laure Pimentel · 54問 · 2年前

1. SERO

1. SERO

54問 • 2年前

Yves Laure Pimentel · 38問 · 2年前

2. PRECIPITATION

2. PRECIPITATION

38問 • 2年前

Yves Laure Pimentel · 17問 · 2年前

3. PASSIVE IMMUNODIFFUSION

3. PASSIVE IMMUNODIFFUSION

17問 • 2年前

Yves Laure Pimentel · 15問 · 2年前

4. OUCHTERLONY

4. OUCHTERLONY

15問 • 2年前

Yves Laure Pimentel · 9問 · 2年前

5. ELECTROPHORETIC TECHNIQUE

5. ELECTROPHORETIC TECHNIQUE

9問 • 2年前

Yves Laure Pimentel · 11問 · 2年前

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

11問 • 2年前

Yves Laure Pimentel · 29問 · 2年前

7. IMMUNOFIXATION ELECTROPHORESIS

7. IMMUNOFIXATION ELECTROPHORESIS

29問 • 2年前